Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Retinal Disorder Treatment Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The market for retinal disorder treatments has experienced substantial expansion in recent years. Projections indicate growth from $13.69 billion in 2025 to $14.86 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.6%. This historical upward trend is largely driven by a surge in age-related macular degeneration cases, a growing global diabetic population, an increase in ophthalmology clinics and specialty hospitals, progress in retinal imaging technologies, and heightened awareness surrounding retinal diseases.
Over the next several years, the retinal disorder treatment market is anticipated to experience significant expansion, with projections indicating it will reach $21.27 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.4%. This forecasted growth is largely fueled by advancements such as the development of long-acting retinal medications, a rise in approvals for novel biologics and gene therapies, improved accessibility to eye care in emerging markets, heightened investments in ophthalmic research, and a growing focus on personalized retinal therapies. Key trends shaping this period include the increasing adoption of anti-VEGF treatments, a movement toward less invasive retinal procedures, a greater preference for sustained-release drug formulations, the expansion of combination therapy strategies, and a growing utilization of home-based vision monitoring tools.
Download A Free Sample Report For Comprehensive Market Insights:
Retinal Disorder Treatment Market Opportunity Drivers: What Is Creating New Revenue Potential?
The rising incidence of diabetes is anticipated to propel expansion in the retinal disorder treatment market moving forward. As a chronic health condition, diabetes involves elevated blood glucose levels due to the body’s insufficient insulin production or ineffective insulin utilization. Diabetic retinopathy stands as the most prevalent retinal issue among diabetics, resulting from retinal blood vessel damage that may cause bleeding, fluid leakage, and the formation of new blood vessels. Treatment for retinal disorders employs lasers to seal off leaking vessels or eliminate abnormal ones. For example, in June 2024, the National Health Service, a UK government department, reported that over half a million (549,000) additional individuals in England were identified as at risk for type 2 diabetes in 2023, raising the total of those with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This marks a notable increase from 3,065,825 in 2022. Consequently, the growing prevalence of diabetes is fueling the expansion of the retinal disorder treatment market.
Retinal Disorder Treatment Market Segmentation Trends And Revenue Drivers
The retinal disorder treatment market covered in this report is segmented –
1) By Type: Macular Degeneration, Diabetic Retinopathy, Other Types
2) By Dosage Form: Gels, Eye Solutions, Capsules And Tablets, Eye Drops, Ointments
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
Subsegments:
1) By Macular Degeneration: Dry Macular Degeneration, Wet Macular Degeneration
2) By Diabetic Retinopathy: Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
3) By Other Types: Retinal Detachment, Retinitis Pigmentosa, Uveitis, Other Retinal Disorders
Retinal Disorder Treatment Market Innovation Trends Driving Future Development
Leading players in the retinal disorder treatment market are actively creating new products, like therapies for geographic atrophy, aimed at reaching broader audiences, boosting sales, and driving revenue growth. Such treatments for geographic atrophy are designed to control symptoms, decelerate disease advancement, and assist patients in handling vision loss. A notable example occurred in August 2023, when Astellas Pharma Inc., a pharmaceutical firm based in Japan, received U.S. Food and Drug Administration (FDA) clearance for IZERVAY. This drug, a groundbreaking complement C5 inhibitor, holds the unique position of being the only approved option for geographic atrophy (GA) that has shown a highly significant reduction (p<0.01) in GA progression rates at the 12-month primary endpoint across two Phase 3 clinical studies. This distinctive attribute confirms IZERVAY (avacincaptad pegol intravitreal solution) as a proven and indicated treatment for GA linked to age-related macular degeneration (AMD).
Retinal Disorder Treatment Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the retinal disorder treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Regeneron Pharmaceuticals Inc., Genentech Inc., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Adverum Biotechnologies Inc., Kodiak Sciences Inc., Acucela Inc., IVERIC bio Inc., Oxurion NV, Graybug Vision Inc., Clearside Biomedical Inc., Ophthotech Corporation, Opthea Limited, PanOptica Inc., ThromboGenics NV
Access The Complete Retinal Disorder Treatment Market Report:
Retinal Disorder Treatment Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the retinal disorder treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal disorder treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model